Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) said Saturday that a phase 4 trial of Dupixent in adults and adolescents showed improvements in signs and symptoms of atopic dermatitis from baseline across many skin tones.
At 24 weeks, 76% of patients achieved an improvement rate of at least 75% in overall disease severity, while 53% achieved clinically meaningful improvement in itch.
Patients experienced a 53% cut from baseline in post-inflammatory hyperpigmentation, the companies said.
Atopic dermatitis is a disease that disproportionately impacts communities of color.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.